Microfluidics News and Research

RSS

CDAS, Prestwick Chemical sign drug discovery research agreement

Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, today announced a strategic partnership between the company's contract research organization, Caliper Discovery Alliances & Services (CDAS), and Prestwick Chemical (Strasbourg, France) to provide customized outsourced medicinal chemistry and in vitro and in vivo preclinical biology programs for drug discovery research.

19 Nov 2009

IBM scientists create one-step point-of-care-diagnostic test based on innovative silicon chip

IBM (IBM) scientists have created a one-step point-of-care-diagnostic test, based on an innovative silicon chip, that requires less sample volume, is significantly faster, portable, easy to use, and can test for many diseases, including one of world's leading causes of death, cardiovascular disease.

18 Nov 2009

Patent number for Microfluidic Valve Mechanism received

Microfluidic Systems, a privately-held company, announced today that they received patent number 7,607,641, entitled "Microfluidic Valve Mechanism". This patent covers a broad set of claims regarding the integration of a diaphragm membrane into a rigid body of a cartridge functioning as both a fluidic seal and cover of the cartridge, and as a valve mechanism for fluidics control within the cartridge.

16 Nov 2009

NIDA supports new drug detection research

Every time a person snorts cocaine, it doesn't just go to his or her head: It also provokes a response in the immune system, creating special biomolecules that may serve as a permanent record of each exposure.

11 Nov 2009

Caliper Life Sciences announces financial results for third quarter ended September 30, 2009

Caliper Life Sciences, Inc. today reported results for its third quarter ended September 30, 2009. GAAP revenues increased by 4% to $32.2 million, from non-GAAP revenues of $31.0 million in the same period of 2008, which represents GAAP revenue of $34.0 million in the third quarter of 2008 reduced by $3.0 million for the impact of divested product lines.

9 Nov 2009

Caliper Discovery Alliances and Services receives a $1.8M funding commitment for the EPA's ToxCast program

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today announced that its Caliper Discovery Alliances and Services (CDAS) unit has been awarded a new funding commitment for $1.8 million under its contract with the Environmental Protection Agency (EPA) for the EPA's ToxCast screening program.

9 Nov 2009

Rice University's new BRC awarded $2M NIH grant to develop an inexpensive test for oral cancer

The National Institutes of Health (NIH) has awarded researchers in Rice University's new BioScience Research Collaborative (BRC) a $2 million Grand Opportunity (GO) grant to develop a fast, inexpensive test for oral cancer that a dentist could perform simply by using a brush to collect a small sample of cells from a patient's mouth.

6 Nov 2009

New biosensor device may help in combating cancer

A powerful new biosensor developed by European researchers will help identify cells in the immune system that actively suppress tumour growth, then put them to use. Enlisting the patient's own immune system would be like sending reinforcements for resistance fighters.

5 Nov 2009

Caliper Life Sciences presents the benefits of its LabChip GX platform

Caliper Life Sciences, Inc., a leading provider of life sciences tools, presented at a training session for reviewers from the United States Food and Drug Administration (FDA) on the benefits of the LabChip GX platform for high throughput screening and characterization assays for biological drugs.

3 Nov 2009

Caliper Life Sciences to use SRU Biosystems’ label-free BIND technology for new functional assays

SRU Biosystems today announced that Caliper Life Sciences will use SRU Biosystems’ label-free BIND® technology to offer new functional assays as part of its Discovery Alliances and Services.

3 Nov 2009

Micronics inks license agreement with Biosearch Technologies

Micronics, Inc., a leading developer of point-of-care molecular diagnostic products, announced today that it has entered into a license agreement with Biosearch Technologies, Inc. (Biosearch) for the right to make, have made, use and sell Micronics’ products that incorporate Biosearch’s proprietary fluorophores and quencher dyes for nucleic acid assays. Under the terms of the worldwide license, Biosearch has granted Micronics a royalty-free use of certain of its chemistries for inclusion in Micronics’ infectious disease tests for sale in underdeveloped countries.

28 Oct 2009

Seminar focuses on approaches to improve small molecule discovery programs

Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, last week held the latest seminar in its "Innovation for Experimentation" series.

23 Oct 2009

Life science tool companies must consider multiple factors to develop strategies for future

Companies involved in the life science tools market must consider a multitude of technologies, economic drivers and societal trends in developing strategies for the future.

21 Oct 2009

Advanced Projects Group and Cellectricon collaborate to produce the Dynaflow HT patch clamp equipment system

The Automation Partnership (TAP), a world leading supplier of innovative automation for life science applications today announced its Advanced Projects Group, has successfully collaborated with Cellectricon, the Swedish provider of innovative screening solutions for drug discovery, to produce fully automated high throughput patch clamp equipment known as the Dynaflow®HT System.

From Cellectricon 14 Oct 2009

Global POC market to increase from $12.8 billion in 2008 to $17.8 billion by 2014, says report

According to a new report distributed by Life Science Intelligence (LSI), the global point-of-care (POC) testing market will experience dramatic growth from $12.8 billion in 2008 to $17.8 billion by 2014.

14 Oct 2009

Geniom RT Analyzer provides accurate diagnosis of multiple sclerosis and lung cancer disorders

Data published in BMC Cancer and PLoS ONE show that microRNA (miRNA) biomarkers provide reliable and highly differentiated diagnosis from blood samples for lung cancer and multiple sclerosis.

14 Oct 2009

NHGRI support research to accelerate development of innovative sequencing technologies

GE Global Research, the technology development arm for the General Electric Company (NYSE: GE), today announced that scientists in their Biosciences Lab have been awarded a second round of funding from the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), to continue research that could reduce the cost and time of sequencing of an entire human genome to less than $1,000, in under a day.

9 Oct 2009

Development of lab-on-chip system for breast cancer detection and therapy

IMEC, a leading European research center in nanotechnology, the Institüt für Mikrotechnik Mainz (IMM), one of the leading European research centers in microfluidics, and their partners within the European Sixth Framework Project MASCOT achieve a major milestone in the development of a lab-on-chip for the detection and therapy evaluation of breast cancer.

8 Oct 2009

Advanced Liquid Logic awarded an NIAID contract to develop a rapid HIV diagnostic device

Advanced Liquid Logic announced today that it has received a large, four-year contract from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, for the development of a rapid, point-of-care, diagnostic device for the detection of HIV in low resource settings.

3 Oct 2009

Incept BioSystems commences human clinical trial of its SMART Embryo Culture System

Incept BioSystems, Inc., a privately-held biomedical device company using patented microfluidic technology developed at the University of Michigan, announced today that it has initiated the first U.S. human clinical trial of its proprietary SMART Embryo Culture System. The microscale SMART technology platform is designed to improve the in vitro manipulation, performance, and viability of embryos for the treatment of patients undergoing in vitro fertilization (IVF).

1 Oct 2009